GH AXIS & LONGEVITY / COLOPHON
About This Reference Desk
A citation-anchored atlas of the research literature on four compounds where the GH axis meets longevity biology — a map of the evidence, not a storefront or a consulting room.
What pureformpeptide is
pureformpeptide is an atlas of the published research on four compounds at the intersection of the growth-hormone axis and longevity research: NAD+ (lead), Ipamorelin, CJC-1295, and MOTS-c.
The site exists to make a fragmented, uneven, and frequently overstated body of literature legible. These four compounds appear together in longevity and performance conversations — and sometimes in the same protocols — but they operate at different biological levels, have radically different evidence bases, and carry very different regulatory profiles. Holding those differences plainly in view is the work this atlas does.
The organizing frame is the GH axis and cellular aging viewed together: hormonal GH secretagogues (Ipamorelin, CJC-1295) at the pituitary level; intracellular metabolic biology at the mitochondrial and coenzyme level (MOTS-c, NAD+). Each compound has a dedicated research page; a compare page lines them up side by side; and a single shared references list aggregates every cited source.
How this desk reads the literature
Three principles govern what appears on this site.
First, every claim is anchored to a numbered citation. Each research statement is tied to a PubMed-indexed journal article or systematic review, with DOIs and PubMed links, collected on the references page. Where a finding comes from a review rather than a primary study, the review is cited as such — and the distinction is noted.
Second, evidence is reported at its actual strength. Doses are described in the species and route they were studied in — for example, studied at 1-3 mg/kg intraperitoneally in ferrets — never scaled to humans or framed as a recommendation. Where evidence is animal-only, single-lab, or rests on a related compound rather than the compound discussed, the text says so. The 2025 Nature Metabolism review's honest appraisal of NAD+ evidence [11] — "human efficacy data remain limited" — is the editorial model for how this desk handles the gap between exciting mechanisms and proven human outcomes.
Third, regulatory and anti-doping status is stated directly. Whether a compound is prohibited in sport, removed from compounding lists, or subject to FDA safety concerns is part of the research record, and it is stated on every compound page — not buried in a footnote.
What the atlas is not
pureformpeptide charts the literature; it does not trade in the compounds it charts. Nothing is sold, supplied, sourced, or brokered here, and there is no affiliate or referral tie to any vendor. There are no clinicians behind it, no diagnoses offered, and no prescriptions or recommendations of any kind.
The compounds discussed here vary considerably in their regulatory standing: NAD+ precursors are legal dietary supplements; Ipamorelin and CJC-1295 are research chemicals that regulators have specifically declined to permit in compounding pharmacy contexts; MOTS-c is a research chemical with entirely preclinical interventional evidence. None is presented as safe, effective, or appropriate for self-directed use.
Readers with health questions should consult a licensed clinician working within their jurisdiction with regulated, evidence-based options. What the atlas offers is an accurate, calibrated map of the literature — what is known, what is not, and what the gap between mechanism and evidence actually looks like.